content
This website is intended for use by patients prescribed Ngenla ▼ (somatrogon) in the UK, and has been developed and funded by Pfizer Ltd.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in the Google Play or Apple App store for how to report side effects.

This information is not intended to be a substitute for advice provided by a healthcare professional. For advice, please consult a healthcare professional.

Adverse event reporting statement can be found at the bottom of this page.
image
content
headline

Ngenla Device Support

disclaimer
Imagery for illustrative use only.
placeholder_icon
placeholder_title
placeholder_body
headline

Ngenla Device Demonstration Video

video_id
6374047952112
account_id
1852113022001
title
Ngenla Device Demonstration Video
poster
load
fast
content
buttons
disclaimer
headline

Downloadable Resources

content
Access useful resources to support you with your Ngenla treatment.
eyebrow
disclaimer
If you have any further questions relating to your medication or device, please speak to your doctor, nurse or pharmacist.
heading

How to use the Ngenla Pen

body
Click here to read step-by-step instructions on how to use your Ngenla pen.
cta
Ngenla User Guide
heading

Ngenla Injection Guide

body
Click here to help you calculate split doses with your Ngenla pen.
cta
Ngenla Injection Guide
headline
content

Adverse Event Reporting


If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Any suspected side effects may also be reported to Pfizer medical information on 01304 616161. By reporting side effects, you can help provide more information to the safety of this medicine.